The optimal treatment for potential AmpC-producing Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, remains unknown. An updated systematic review and meta-analysis of studies comparing beta-lactam/beta-lactamase inhibitors with carbapenems in the treatment of bloodstream infections with these pathogens found no significant difference in 30-day mortality (OR, 1.13; 95% CI, 0.58 -2.20).
Widespread use of third-generation cephalosporins has resulted in the emergence of organisms that possess broad spectrum beta-lactamases. These enzymes are classified according to their amino acid structure and display variable affinity to different beta-lactams. Certain Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, can carry a gene, ampC, which encodes a broad-spectrum beta-lactamase that most beta-lactamase inhibitors cannot inactivate. When exposed to the selective pressure of beta-lactam antibiotics, these organisms have the potential to express this enzyme 10-to 100-fold above baseline levels [1] .
The most recent Clinical and Laboratory Standard Institute (CLSI) guidelines suggest reporting susceptibility data for Enterobacter spp., Citrobacter spp., and Serratia spp. based on phenotypic testing. Although these organisms may become resistant after initiation of therapy, the CLSI guidelines do not recommend initial supplemental investigations for inducible resistance [2] . Yet, some studies suggest that hydrolysable betalactam therapy, including third-generation cephalosporins and beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations, may be associated with an increased risk of treatment failure in cases of infections caused by potential AmpC-producing organisms [3] . Consequently, their use is often discouraged in clinical practice [4] and many clinical laboratories either directly edit susceptibility reports or issue warning messages favoring the use of other antibiotics. For this reason, clinicians may prescribe alternate therapies, including carbapenems, which may favor the emergence of other multidrug resistant organisms.
Previous studies evaluating BL/BLIs in the treatment of potential AmpC-producing organisms are of relatively small sample size and have had varying results. To further contribute to our knowledge on this topic, we updated a previous systematic review and meta-analysis of studies on this issue [5] and included results from a retrospective chart review of cases in our institution. The goal was to update the estimated risk of 30-day mortality among patients who received BL/BLIs as definitive therapy compared to those who received carbapenem therapy.
METHODS
This meta-analysis was performed according to the Metaanalysis Of Observational Studies in Epidemiology (MOOSE) guidelines [6] . We updated a previously published study comparing carbapenems to BL/BLIs for the definitive therapy [5] of bloodstream infections (BSIs) involving potential AmpCproducing Enterobacteriaceae. We extended the authors' original search strategy, which ended in August 2015, up to October 2018 and included the results from our own unpublished retrospective cohort (described in the Supplementary Appendix). We queried electronic databases, including EMBASE, PubMed, the Cochrane database, and Scopus for articles of interest. The search protocol used was the following: (Enterobacter OR Serratia OR Citrobacter OR Providencia OR Morganella) AND (bacteremia OR bacteraemia OR bloodstream infection) AND (piperacillin/tazobactam OR ticarcillin/clavulanate OR cefepime OR carbapenem OR betalactam/beta-lactamase inhibitor OR quinolone OR mortality). Searches were limited to human studies published in English or French. Additional articles were identified from references of included studies.
Studies were included if they reported on patients with BSIs caused by organisms that may harbor inducible AmpC resistance (Serratia, Providencia, Citrobacter, Enterobacter, or Morganella species), where patients were definitively treated with either a carbapenem or a BL/BLI, and where mortality was the primary outcome. There were no specific study selection criteria based on study design or study quality. Two reviewers (M.P.C. and T.C.L.) screened the potentially relevant studies by title and abstract, and then M.P.C. assessed their eligibility and quality by full-text review. Two authors (M.P.C. and K.D.) then independently extracted data from each relevant study. Data on mortality by treatment assignment was extracted from each source paper. When this was unavailable, the corresponding authors were contacted for additional data for inclusion. There were no discrepancies in extraction. Study quality was assessed using the NewcastleOttawa Quality Assessment Scale [7] , but there was no quality threshold to be included.
Outcome Measures and Statistical Analysis
Unadjusted odds ratios (ORs) for mortality within 30 days were calculated between BL/BLIs versus carbapenems as definitive therapy in the treatment of BSI with potential AmpC-producing Abbreviations: BSI, bloodstream infection; CAD, coronary artery disease; CCI, Charlson comorbidity index; CHF, congestive heart failure; CKD, chronic kidney disease; CLABSI, central-line associated bloodstream infection; COPD, chronic obstructive pulmonary disease; CTD, connective tissue disease; CVD, cardiovascular disease; DM, diabetes mellitus; HCF, healthcare facility; IAI, Intra-abdominal infection; ICU, intensive care unit; IQR, interquartile range; LRTI/VAP, lower respiratory tract infection/Ventilatorassociated pneumonia; NOS, Newcastle-Ottawa Quality Assessment Scale; RRT, Renal replacement therapy; SAPS, Simplified Acute Physiology Score; SOFA, Sequential organ failure assessment; SSTI, skin and soft-tissue infection. organisms. These ORs were pooled using a random effects model. Heterogeneity was assessed using I 2 . All calculations were performed in Stata version 15 (StataCorp, College Station, TX) using the "metan" command [8] .
RESULTS
The search strategy yielded 75 potential studies for inclusion (see Figure 1 in the Supplementary Appendix). A complete review of the articles yielded 5 new studies [9] [10] [11] [12] [13] , which were used to update the previous meta-analysis of 8 studies [5] comprising 665 patients. One study included patients who were already reported in the previous meta-analysis [11] and so to avoid double counting we only included those patients in the later group. In total, 13 studies (including our unpublished data) and 1021 patients were included in the meta-analysis.
Characteristics of Studies from the Updated Search Strategy
All identified studies were observational in nature. Study characteristics, including design, time-period, bacterial species, population characteristics, bacteremia characteristics, and outcome measures are summarized in Table 1 , which also includes the 8 studies from the previous meta-analysis. Five of the 6 studies from the expanded search, including our patient cohort, reported the proportion of isolates with an AmpC phenotype, which varied from 18% to 92%. The study quality and risk of selection bias were moderate for all studies, as all were single center.
Outcome Measures
One study was excluded from the final analysis due to the absence of events in either treatment arm [13] . Meta-analysis of the 12 remaining studies yielded a pooled OR for death within 30 days for patients receiving a BL/BLI as definitive therapy of 1.04 (95% CI 0.54-2.02). There was moderate heterogeneity within the studies (I 2 = 56.0%, P = .009) mainly due to studies published in 2014 where carbapenem use was favourable. The Forrest plot is presented in Figure 2 .
DISCUSSION
We updated a previous systematic review and meta-analysis and were able to increase the number of included patients by 54%. Although the results of this updated analysis substantiate the hypothesis that a BL/BLI may be a reasonable alternative to carbapenems in the definitive treatment of BSI with
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Huh (2014) AGAR (2014) Chaubey (2014) Lin (2015) Moy (2016) Cheng, L (2017) Erlanger (2017) Harris (2017) Cheng, MP (2018) Noguchi (2017) Overall (I-squared = 56.0%, P = .0009) potential AmpC-producing Enterobacteriaceae, some uncertainty remains. This is largely because the proportion of isolates that harbor the AmpC gene, and the degree to which the enzyme becomes expressed during treatment, remains largely unknown. Third-generation cephalosporins have previously been associated with adverse patient outcomes in the treatment of potential AmpC-producing organisms [14] ; however, this was prior to the revision of the ceftriaxone breakpoints and may no longer be true. These conservative breakpoints may now label organisms with a greater propensity to fail hydrolysable betalactam therapy as resistant at the onset of treatment. Moreover, piperacillin-tazobactam, because it is a relatively weak inducer of AmpC [15] , may be more likely than ceftriaxone to have favorable outcomes. Our results must be interpreted with caution, as the published studies were all retrospective in nature and conducted using available clinical data. As the CLSI guidelines do not recommend routine genotypic and phenotypic testing for AmpC production, we were unable to determine what portion of the included isolates were hyperproducing AmpC enzymes. However, our findings remain generalizable as many centers do not routinely test for AmpC production. Different studies had unequal organism representation: Enterobacter spp. was the most common organism studied and also has one of the higher potentials for AmpC enzyme expression [16] . As such, our findings presumably are generalizable to other organisms with lesser potential for enzyme expression. Because our results may have over-estimated any negative effect of AmpC production, our results suggest that BL/BLIs may remain a reasonable carbapenem-preserving strategy in the treatment of potential AmpC-producing organisms. However, given that the 95% confidence limits do not exclude a potentially higher mortality rate with BL/BLI, this may be limited outside of a clinical trial to those patients who have had source control and already demonstrated a clinical response to antibiotics.
The strength of this systematic review and meta-analysis is that it now includes many patients with BSIs with potential AmpC-producing Enterobacteriaceae arising after the CLSI breakpoint revision [5] . It also comprises many studies from different countries with a sizable number of patients treated with BL/BLIs to compare this treatment strategy with carbapenems. In the absence of randomized clinical trial data comparing BL/ BLI to carbapenems, we believe this study is an important contribution to our limited knowledge on this issue.
Based on our meta-analysis, and accounting for all the limitations of observational studies, including confounding by severity or indication, we were not able to demonstrate that BL/ BLIs result in inferior outcomes for BSIs with potential AmpCproducing organisms. Although there are theoretical advantages to using a carbapenem, we do not know if this advantage is attenuated by the selective pressure on other carbapenem-resistant organisms [17] or the development of de novo carbapenem resistance via porin mutations in AmpC hyperproducers. As we await the results of an ongoing pilot randomized noninferiority trial on this subject [18] , our results provide additional clinical equipoise for a future multicenter, randomized controlled trial to address the issue of whether BL/BLIs present a valid definitive treatment option for these bacteria.
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